Omega Funds
Actively deployingFund manager profile
Omega Funds is a venture fund manager. SEC filings show 1 venture fund on record, most recently Omega Fund VIII, L.P. filed April 2025.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
What they invest in
from 7 of 7 portfolio companiesMedical Devices ×5Biotech ×4Deep Tech ×3AI & Machine Learning ×2Advanced Manufacturing ×1Cybersecurity ×1Digital Health ×1Enterprise Software ×1
HQs:United States×9Colombia×1
Investments · 7 tracked
founders shown can be your intro pathAntares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases. The company combines proprietary chemistry, target biology, and predictive sciences to advance drug candidates for cancer and other therapeutic areas.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Adam Friedman(Chief Executive Officer)
Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment. The company's lead program is a dual-payload HER2-targeted ADC designed to deliver drug combinations to tumor cells.
BiotechMedical DevicesSeattle, US
Zachary Hornby(Chief Executive Officer)Piers Ingram(President, Co-Founder)Jerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)
GelSight develops high-resolution tactile imaging and surface metrology technology for measuring and analyzing surface properties in manufacturing. The platform serves aerospace, automotive, electronics, and research sectors with non-destructive mobile measurement capabilities that improve product quality assessment and innovation speed.
Advanced ManufacturingAI & Machine LearningDeep TechHardware<UNKNOWN>, US
<UNKNOWN>
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications. The company works with academic founders and institutional investors focused on advancing gene therapy treatments.
BiotechDeep TechMedical Devices
Luke Gilbert, PhDKeith Joung, MD, PhDDavid Liu, PhDAngelo Lombardo, PhD
Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering. The company is led by a team with a track record of 35+ drug approvals.
BiotechMedical Devices
XII Medical develops neuromodulation therapies for treating obstructive sleep apnea, focusing on simplifying treatment options and improving patient outcomes.
Deep TechDigital HealthMedical Devices
Board seats · per SEC filings · 6
what is this? ⓘ$110.7M raise · filed Jan 2026 · via Claudio Nessi
$69.1M raise · filed Jan 2026 · via Claudio Nessi
$75M raise · filed Jul 2025 · via Otello D. Stampacchia, Otello Stampacchia
$165M raise · filed Aug 2024 · via Francesco Draetta, Otello Stampacchia
$150M raise · filed Jul 2024 · via Otello Joseph Stampacchia, Otello Stampacchia
$101.8M raise · filed Sep 2023 · via Francesco T. Draetta
Inferred from directors named on each company's SEC Form D — public regulatory data, not a portfolio list published by the firm.